The landscape of inherited retinal diseases (IRDs) is continuously evolving, bringing renewed hope to patients and families affected by these sight-threatening conditions. Recent announcements from Belite Bio and Opus Genetics highlight significant progress in the development of new therapies for Stargardt disease and Leber Congenital Amaurosis (LCA), two forms of IRDs that lead to severe vision loss. These advancements underscore the rapid pace of research and the potential for groundbreaking treatments to emerge in the near future.
Stargardt Disease: Oral Therapy Shows Promise in Phase 3 Trial
Belite Bio has presented updated positive secondary endpoint data from its Phase 3 DRAGON trial for tinlarebant (LBS-008), an oral medication designed to treat Stargardt disease type 1 (STGD1). Stargardt disease is the most common inherited juvenile macular degeneration, typically causing progressive central vision loss in childhood or adolescence due to the accumulation of toxic byproducts in the retina. Currently, there are no approved treatments for Stargardt disease.
Tinlarebant works by lowering levels of retinol binding protein 4 (RBP4), which transports vitamin A to the eye. By reducing vitamin A accumulation, the therapy aims to decrease the formation of toxic bisretinoids that contribute to STGD1 progression. The DRAGON trial previously met its primary endpoint, demonstrating a statistically significant 35.7% slowing of definitively decreased autofluorescence (DDAF) lesion growth compared to placebo over 25 months. Updated data further showed that quantitative autofluorescence (qAF), a marker for toxic bisretinoid accumulation, remained stable or slightly decreased in tinlarebant-treated patients, while placebo-treated patients saw an approximate 20% increase.
This oral therapy has received multiple FDA designations, including Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug, which could expedite its review process. Belite Bio has already completed a rolling submission of its new drug application (NDA) to the FDA for tinlarebant in STGD1, positioning it as a potential first-ever approved treatment for this condition.
LCA Gene Therapy: Phase 3 Enrollment Complete for OPGx-LCA5
In another significant development, Opus Genetics has announced the completion of patient enrollment in its registrational Phase 3 clinical trial for OPGx-LCA5, an adeno-associated virus (AAV) gene therapy targeting Leber Congenital Amaurosis type 5 (LCA5). LCA is a group of rare inherited retinal diseases that cause severe vision loss or blindness from birth or early infancy. While Luxturna (voretigene neparvovec) is an FDA-approved gene therapy for LCA caused by RPE65 mutations, treatments for other genetic forms of LCA are still under investigation.
OPGx-LCA5 is designed as a one-time subretinal administration to deliver a functional LCA5 gene to the outer retina, addressing the underlying genetic cause of LCA5-associated IRD. The Phase 3 study design was developed in collaboration with the FDA through its Rare Disease Evidence Principles (RDEP) program, incorporating innovative approaches suitable for ultra-rare diseases, such as a six-month run-in period where patients serve as their own controls.
Opus Genetics expects to initiate dosing of OPGx-LCA5 in the fourth quarter of 2026, with topline six-month efficacy data anticipated by the end of 2027. This therapy also holds several FDA designations, including Rare Pediatric Disease, Orphan Drug, and Regenerative Medicine Advanced Therapy (RMAT), indicating its potential to address a significant unmet medical need. If successful, OPGx-LCA5 could become the first approved treatment specifically for patients with LCA5-associated inherited retinal disease.
A Future of Expanding Treatment Options
These recent milestones represent crucial steps forward in the fight against inherited retinal diseases. The progress with tinlarebant for Stargardt disease offers the prospect of an oral medication to slow disease progression, a significant advancement for a condition currently lacking approved therapies. Simultaneously, the completion of enrollment for OPGx-LCA5's Phase 3 trial brings a potential gene therapy closer to patients with a specific form of LCA. These developments, alongside ongoing research into gene editing and stem cell therapies, paint a hopeful picture for a future with more diverse and effective treatment options for individuals living with IRDs. The continued dedication of researchers, pharmaceutical companies, and regulatory bodies is paving the way for a new era of vision preservation and restoration.